



## *Curriculum Vitae*

### **Heading:**

- **Name & Date of birth** : Farhad Hosseinpanah Ghasabeh / 1<sup>st</sup> January 1968
- **Current Address**: Obesity Research Center, Research Institute for endocrine sciences, Shahid Beheshti University of Medical Sciences. Taleghani Hospital Tehran – Iran P.O.Box: 19395-4763
- **Current Phone**: +982122409309
- **Office Phone**: +982122432500
- **Fax**: +982122402463
- **Permanent Address**: Obesity Research Center, Research Institute for endocrine sciences, Shaheed Beheshti University of Medical Sciences. Taleghani Hospital Tehran – Iran P.O.Box: 19395-4763
- 

### **Education:**

**Name of College/University**: Shahid Beheshti University of Medical Sciences Tehran Iran Year of Graduation: 1992

- Specialty of Internal Medicine 1996
- Sub specialty of endocrinology and metabolism 1999
- **Thesis Title**: “Determination of serum calcium & phosphorus and albumin in school children of 23 provinces in Iran in 1995”\_

### **Honors of Awards:**

- **First rank of National Board of Internal Medicine in 1996**
- **First rank of National Board of Endocrinology in 1999**

### **Relevant Experience:**

**Organization**: Faculty Member of Shahid Beheshti University of Medical Sciences Tehran Iran  
Employed/Worked: 2001

**Title**: Associate Professor

**Description of Duties**: Education and Research

## Other Experience:

- Evidence Based Medicine
- Research Methodology
- Medical Scientific Writing
- 

## Professional Associations:

**Name:** Organization: Iranian Endocrine Society-Tehran-Iran

**Positions Held:** Member of Executive Committee

**Name:** Iran obesity society

**Positions Held:** Former member of Executive Committee

**Name:** Obesity Research Center, Research institute for Endocrine Science, Shahid Beheshti University of Medical Sciences Tehran Iran

**Positions Held:** Former director

## Publications:

### Articles:

1. Tasdighi E, Barzin M, Mahdavi M, Valizadeh M, Dehghan P, Moghaddam AM, Azizi F, Momenan AA, **Hosseinpanah F**. *Association of childhood obesity phenotypes with early adulthood Carotid Intima-Media Thickness (CIMT): Tehran lipid and glucose study*. Nutr Metab Cardiovasc Dis. 2022 Jan;32(1):249-257.
2. Mousapour P, Barzin M, Valizadeh M, Mahdavi M, Hadaegh F, Azizi F, **Hosseinpanah F**. *Wrist circumference as a novel predictor of transition from metabolically healthy to unhealthy phenotype in overweight/obese adults: a gender-stratified 15.5-year follow-up*. BMC Public Health. 2021 Dec 13;21(1):2276.
3. Valizadeh M, Tasdighi E, Barzin M, Hariri R, Mahdavi M, Dehghan P, Momeni Moghaddam A, Azizi F, **Hosseinpanah F**. *Association of childhood metabolic syndrome and metabolic phenotypes with the carotid intima-media thickness (CIMT) in early adulthood: Tehran lipid and glucose study*. Int J Cardiol. 2021 Dec 10:S0167-5273(21)02003-9.
4. Barzin M, Andalib A, Khalaj A, Mahdavi M, Valizadeh M, Mousapour P, **Hosseinpanah F**. *Predictive Factors of Cholelithiasis After Prophylactic Administration of Ursodeoxycholic Acid Following Laparoscopic Bariatric Surgery: Tehran Obesity Treatment Study*. Obes Surg. 2021 Nov 23.
5. Asgari S, Khalili D, **Hosseinpanah F**, Hadaegh F. *Prediction Models for Type 2 Diabetes Risk in the General Population: A Systematic Review of Observational Studies*. Int J Endocrinol Metab. 2021 Mar 22;19(3):e109206.

6. Dehghani M, Davoodi Z, Bidari F, Moghaddam AM, Khalili D, Bahrami-Motlagh H, Jamali E, Alamdari S, **Hosseinpanah F**, Hedayati M, Valizadeh M. *Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study.* BMC Endocr Disord. 2021 Sep 16;21(1):186. doi: 10.1186/s12902-021-00850-2.
7. Hassabi M, Esteghamati A, Halabchi F, Abedi-Yekta AH, Mahdavi B, Hassanmirzaie B, **Hosseinpanah F**, Valizadeh M. *Iranian National Clinical Practice Guideline for Exercise in Patients with Diabetes.* Int J Endocrinol Metab. 2021 Apr 26;19(3):e109021.
8. **Hosseinpanah F**, Seyedhoseinpour A, Barzin M, Mahdavi M, Tasdighi E, Dehghan P, Momeni Moghaddam A, Azizi F, Valizadeh M\*. *Comparison analysis of childhood body mass index cut-offs in predicting adulthood carotid intima media thickness: Tehran lipid and glucose study.* BMC Pediatr. 2021 Nov 6;21(1):494.
9. Barzin M, Heidari Almasi M, Mahdavi M, Khalaj A, Valizadeh M, **Hosseinpanah F**\*. *Body Composition Changes Following Sleeve Gastrectomy Vs. One-Anastomosis Gastric Bypass: Tehran Obesity Treatment Study (TOTS).* Obes Surg. 2021 Oct 12.
10. Babaniamansour S, Aliniagerdroudbari E, Afrakhteh M, **Hosseinpanah F**, Farzaneh F, Niroomand M\*. *Can fasting plasma glucose replace oral glucose-tolerance test for diagnosis of gestational diabetes mellitus?* Diabetol Int. 2021 Jan 2;12(3):277-285.
11. Yaghoobpour K, Tasdighi E, Abdi H, Barzin M, Mahdavi M, Valizadeh M, Azizi F, **Hosseinpanah F**\*. *Association of obesity phenotypes in adolescents and incidence of early adulthood type 2 diabetes mellitus: Tehran lipid and glucose study.* Pediatr Diabetes. 2021 Nov;22(7):937-945.
12. Rostami M, Simbar M, Amiri M, Bidhendi-Yarandi R, **Hosseinpanah F**, Ramezani Tehrani F\*. *The optimal cut-off point of vitamin D for pregnancy outcomes using a generalized additive model.* Clin Nutr. 2021 Apr;40(4):2145-2153.
13. Jalali-Farahani S, Amiri P\*, Lashkari B, Cheraghi L, **Hosseinpanah F**, Azizi F. *Prognostic value of different maternal obesity phenotypes in predicting offspring obesity in a family-based cohort study.* BMC Public Health. 2021 May 8;21(1):885.
14. Zahedi M, Asghari G, Mirmiran P, **Hosseinpanah F**\*. *Case Report: Management of a Patient With Chylomicronemia Syndrome During Pregnancy With Medical Nutrition Therapy.* Front Nutr. 2021 Mar 5;8:602938.
15. Mousapour P, Tasdighi E, Khalaj A, Mahdavi M, Valizadeh M, Taheri H, **Hosseinpanah F**, Barzin M\*. *Sex disparity in laparoscopic bariatric surgery outcomes: a matched-pair cohort analysis.* Sci Rep. 2021 Jun 17;11(1):12809.
16. Aryannezhad S, **Hosseinpanah F**, Khalaj A, Mahdavi M, Valizadeh M, Akhavirad SMB, Barzin M\*. *Comparison of the one-year outcomes of bariatric surgery in adolescents and young adults: a matched case-control study, Tehran Obesity Treatment Study (TOTS).* Surg Today. 2021 Apr 10. doi: 10.1007/s00595-021-02281-x.
17. Valizadeh M, **Hosseinpanah F**\*, Ramezani Tehrani F, Abdi H, Mehran L, Hadaegh F, Amouzegar A, Sarvghadi F, Azizi F; *Iranian Endocrine Society Task Force. Iranian Endocrine Society Guidelines for Screening, Diagnosis, and Management of Gestational*

*Diabetes Mellitus*. Int J Endocrinol Metab. 2020 Dec 23;19(1):e107906. doi: 10.5812/ijem.107906. eCollection 2021 Jan.

18. Mehrabi F, Amiri P\*, Cheraghi L, Kheradmand A, **Hosseinpah F**, Azizi F. *Emotional states of different obesity phenotypes: a sex-specific study in a west-Asian population*. BMC Psychiatry. 2021 Mar 4;21(1):124.
19. Hadaegh F\*, Asgari S, Toreyhi H, Eskandari F, Fahimfar N, Bozorgmanesh M, **Hosseinpah F**, Azizi F. *Sex-specific incidence rates and risk factors for fracture: A 16-year follow-up from the Tehran lipid and glucose study*. Bone. 2021 May;146:115869.
20. Asghari G, Yuzbashian E, Wagner CL, Park Y, Mirmiran P\*, **Hosseinpah F\***. *Daily vitamin D3 in overweight and obese children and adolescents: a randomized controlled trial*. Eur J Nutr. 2021 Jan 11. doi: 10.1007/s00394-020-02406-x.
21. Aryannezhad S, Khalaj A, **Hosseinpah F**, Mahdavi M, Valizadeh M, Barzin M\*. *One-year outcomes of bariatric surgery in older adults: A case-matched analysis based on the Tehran Obesity Treatment Study*. Surg Today. 2021 Jan;51(1):61-69.
22. Mousapour P, Barzin M, Valizadeh M, Mahdavi M, Azizi F, **Hosseinpah F\***. *Comparison of the Modification of Diet in Renal Disease Study and Chronic Kidney Disease Epidemiology Collaboration Equations for Detection of Cardiovascular Risk: Tehran Lipid and Glucose Study*. Int J Endocrinol Metab. 2020 Nov 22;18(4):e101977.
23. **Hosseinpah F\***, Tasdighi E, Barzin M, Mahdavi M, Ghanbarian A, Valizadeh M, Azizi F. *The association between transition from metabolically healthy obesity to metabolic syndrome, and incidence of cardiovascular disease: Tehran lipid and glucose study*. PLoS One. 2020 Sep 18;15(9):e0239164.
24. Gharooi Ahangar O, Javanrouh N, Daneshpour MS, Barzin M, Valizadeh M, Azizi F, **Hosseinpah F\***. *Genetic markers and continuity of healthy metabolic status: Tehran cardio-metabolic genetic study (TCGS)*. Sci Rep. 2020 Aug 12;10(1):13600.
25. Rostami M, Simbar M, Amiri M, Bidhendi-Yarandi R, **Hosseinpah F**, Ramezani Tehrani F \*. *The optimal cut-off point of vitamin D for pregnancy outcomes using a generalized additive model*. Clin Nutr. 2021 Apr;40(4):2145-2153.
26. Mirmiran P, Moslehi N \*, **Hosseinpah F**, Sarbazi N, Azizi F. *Dietary determinants of unhealthy metabolic phenotype in normal weight and overweight/obese adults: results of a prospective study*. Int J Food Sci Nutr. 2020 Nov;71(7):891-901.
27. Ziadlou M, Hosseini-Esfahani F, Mozaffari Khosravi H, **Hosseinpah F**, Barzin M, Khalaj A, Valizadeh M\*. *Dietary macro- and micro-nutrients intake adequacy at 6th and 12th month post-bariatric surgery*. BMC Surg. 2020 Oct 12;20(1):232.
28. Malek M, **Hosseinpah F**, Aghaei Meybodi HR, Jahed SA, Hadaegh F, Sharghi S, Esteghamati A, Khamseh ME \*. *Diabetes Management during the COVID-19 Pandemic: An Iranian Expert Opinion Statement*. Arch Iran Med. 2020 Aug 1;23(8):564-567.
29. Khalaj A, Tasdighi E, **Hosseinpah F**, Mahdavi M, Valizadeh M, Farahmand E, Taheri H, Barzin M\*. *Two-year outcomes of sleeve gastrectomy versus gastric bypass: first report based on Tehran obesity treatment study (TOTS)*. BMC Surg. 2020 Jul 20;20(1):160.

30. Mousapour P, Valizadeh M, Mahdavi M, Saadat N, Barzin M\*, Azizi F, **Hosseinpanah F**. *Trends in the Prevalence of Severe Obesity among Tehranian Adults: Tehran Lipid and Glucose Study, 1999-2017*. Arch Iran Med. 2020 Jun 1;23(6):378-385.
31. Khalaj A, Mousapour P, Motamedi MAK, Mahdavi M, Valizadeh M, **Hosseinpanah F**, Barzin M\*. *Comparing the Efficacy and Safety of Roux-en-Y Gastric Bypass with One-Anastomosis Gastric Bypass with a Biliopancreatic Limb of 200 or 160 cm: 1-Year Results of the Tehran Obesity Treatment Study (TOTS)*. Obes Surg. 2020 May 14. doi: 10.1007/s11695-020-04681-3.
32. Shahali A, Tasdighi E, Barzin M, Mahdavi M, Valizadeh M, Niroomand M, Azizi F, **Hosseinpanah F\***. *Abdominal obesity phenotypes and risk of kidney function decline: Tehran Lipid and Glucose Study*. Obes Res Clin Pract. 2020 Mar-Apr;14(2):168-175.
33. Barzin M, Mousapour P, Khalaj A, Mahdavi M, Valizadeh M, **Hosseinpanah F\***. *The Relationship Between Preoperative Kidney Function and Weight Loss After Bariatric Surgery in Patients with Estimated Glomerular Filtration Rate  $\geq 30$  mL/min: Tehran Obesity Treatment Study*. Obes Surg. 2020 May;30(5):1859-1865. doi: 10.1007/s11695-020-04407-5.
34. Moslehi N\*, Golzarand M, **Hosseinpanah F**, Mirmiran P\*, Azizi F. *Dietary intakes of flavonoids and carotenoids and the risk of developing an unhealthy metabolic phenotype*. Food Funct. 2020 Apr 30;11(4):3451-3458.
35. Mirmiran P, Moslehi N\*, **Hosseinpanah F**, Sarbazi N, Azizi F. *Dietary determinants of unhealthy metabolic phenotype in normal weight and overweight/obese adults: results of a prospective study*. Int J Food Sci Nutr. 2020 Apr 1:1-11.
36. Mousapour P, Barzin M, Valizadeh M, Mahdavi M, Azizi F, **Hosseinpanah F\***. *Predictive performance of lipid accumulation product and visceral adiposity index for renal function decline in non-diabetic adults, an 8.6-year follow-up*. Clin Exp Nephrol. 2020 Mar;24(3):225-234.
37. Piri Z, Barzin M, Mahdavi M, Guity K, Azizi F, **Hosseinpanah F\***, Valizadeh M\*. *The role of childhood BMI in predicting early adulthood dysglycemia: Tehran lipid and glucose study*. Nutr Metab Cardiovasc Dis. 2020 Feb 10;30(2):313-319.
38. Barzin M, Aryannezhad S, Khalaj A, Mahdavi M, Valizadeh M, Ghareh S, Azizi F, **Hosseinpanah F\***. *Effects of bariatric surgery in different obesity phenotypes: Tehran Obesity Treatment Study (TOTS)*. Obes Surg. 2020 Feb;30(2):461-469.
39. **Hosseinpanah. F**, Serahati S, Barzin M, Aryannezhad S, Rezaie M, Valizadeh M, Azizi F. *Trends of Obesity in 10-Years of Follow-up among Tehranian Children and Adolescents: Tehran Lipid and Glucose Study (TLGS)*. Iran J Public Health. 2019 Sep; 48 (9):1714-1722.
40. Asghari G, **Hosseinpanah. F**, Serahati S, Haghgi S, Azizi F. *Association between obesity phenotypes in adolescents and adult metabolic syndrome: Tehran Lipid and Glucose Study*. Br J Nutr. 2019 Sep; 11: 1-18.
41. Azizi F, Hadaeigh F, **Hosseinpanah. F**..., Khalili D. *Metabolic health in the Middle East and north Africa*. Lancet Diabetes Endocrinol. 2019 Aug 14.
42. Chehregosha H, Khamseh ME, Malek M, **Hosseinpanah F**, Ismail-Beigi F. *A View Beyond HbA1c: Role of Continuous Glucose Monitoring*. Diabetes Ther. 2019 Jun;10(3):853-863.
43. Asghari G, Mirmiran P, Yuzbashian E, Dehghan P, Mahdavi M, Tohidi M, Wagner CL, Neyestani T, **Hosseinpanah F**, Azizi F. *Association of circulating 25-hydroxyvitamin D*

- and parathyroid hormone with carotid intima media thickness in children and adolescents with excess weight. J Steroid Biochem Mol Biol. 2019 Apr;188:117-123.*
44. Niroomand M, Fotouhi A, Irannejad N, **Hosseinpahan F**. *Does high-dose vitamin D supplementation impact insulin resistance and risk of development of diabetes in patients with pre-diabetes? A double-blind randomized clinical trial. Diabetes Res Clin Pract. 2019 Feb;148:1-9.*
  45. Ramezani Tehrani F, Minooe S, Rostami M, Bidhendi Yarandi R, **Hosseinpahan F**. *Response to Letter to the Editor: "Effectiveness of Prenatal Vitamin D Deficiency Screening and Treatment Program: A Stratified Randomized Field Trial". J Clin Endocrinol Metab. 2019 Feb 1;104(2):339-340.*
  46. Motamedi MAK, Khalaj A, Mahdavi M, Valizadeh M, **Hosseinpahan F**, Barzin M. *Longitudinal Comparison of the Effect of Gastric Bypass to Sleeve Gastrectomy on Liver Function in a Bariatric Cohort: Tehran Obesity Treatment Study (TOTS). Obes Surg. 2019 Feb;29(2):511-518.*
  47. Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, Gutierrez OM, **Hosseinpahan F**, Iseki K, Kenealy T, Klein B, Kronenberg F, Lee BJ, Li Y, Miura K, Navaneethan SD, Roderick PJ, Valdivielso JM, Visseren FLJ, Zhang L, Gansevoort RT, Hallan SI, Levey AS, Matsushita K, Shalev V, Woodward M; CKD Prognosis Consortium (CKD-PC). *Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019 Jan 10;364.*
  48. Ghasemi A, Bahadoran Z, Zadeh-Vakili A, Montazeri SA, **Hosseinpahan F**. *The Principles of Biomedical Scientific Writing: Materials and Methods. Int J Endocrinol Metab. 2019 Jan 28;17(1).*
  49. Behboudi-Gandevani S, Ramezani Tehrani F, **Hosseinpahan F**, Khalili D, Cheraghi L, Kazemijaliliseh H, Azizi F. *Cardiometabolic risks in polycystic ovary syndrome: long-term population-based follow-up study. Fertil Steril. 2018 Dec;110(7):1377-1386.*
  50. Barzin M, Piri Z, Serahati S, Valizadeh M, Azizi F, **Hosseinpahan F**. *Incidence of abdominal obesity and its risk factors among Tehranian adults. Public Health Nutr. 2018 Dec;21(17).*
  51. Asghari G, Dehghan P, Mirmiran P, Yuzbashian E, Mahdavi M, Tohidi M, Neyestani TR, **Hosseinpahan F**, Azizi F. *Insulin metabolism markers are predictors of subclinical atherosclerosis among overweight and obese children and adolescents. BMC Pediatr. 2018 Nov 23;18(1):368.*
  52. Eftekharzadeh A, **Hosseinpahan F**, Valizadeh M, Barzin M, Mahdavi M, Azizi F. *Legacy of the Tehran Lipid and Glucose Study: Chronic Kidney Disease. Int J Endocrinol Metab. 2018 Oct 31;16(4 Suppl).*
  53. Barzin M, Valizadeh M, Serahati S, Mahdavi M, Azizi F, **Hosseinpahan F**. *Overweight and Obesity: Findings from 20 Years of the Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2018 Oct 23;16(4 Suppl).*
  54. Salehinia F, Abdi H, Hadaegh F, Serahati S, Valizadeh M, Azizi F, **Hosseinpahan F**. *Abdominal obesity phenotypes and incident diabetes over 12 years of follow-up: The Tehran Lipid and glucose study. Diabetes Res Clin Pract. 2018 Oct 21;144:17-24.*
  55. Asghari G, Farhadnejad H, **Hosseinpahan F**, Moslehi N, Mirmiran P, Azizi F. *Effect of vitamin D supplementation on serum 25-hydroxyvitamin D concentration in children and adolescents: a systematic review and meta-analysis protocol. BMJ Open. 2018 Sep 19;8(9).*

56. Amiri P, Jalali-Farahani S, Rezaei M, Cheraghi L, **Hosseinpahan F**, Azizi F. *Which obesity phenotypes predict poor health-related quality of life in adult men and women? Tehran Lipid and Glucose Study*. PLoS One. 2018 Sep 12;13(9)
57. Rostami M, Tehrani FR, Simbar M, Bidhendi Yarandi R, Minooe S, Hollis BW, **Hosseinpahan F**. *Effectiveness of Prenatal Vitamin D Deficiency Screening and Treatment Program: A Stratified Randomized Field Trial*. J Clin Endocrinol Metab. 2018 Aug 1;103(8):2936-2948.
58. Asghari G, Khalaj A, Ghadimi M, Mahdavi M, Farhadnejad H, Valizadeh M, Azizi F, Barzin M, **Hosseinpahan F**. *Prevalence of Micronutrient Deficiencies Prior to Bariatric Surgery: Tehran Obesity Treatment Study (TOTS)*. Obes Surg. 2018 Aug; 28(8)
59. Barzin M, Aryannezhad S, Serahati S, Beikyazdi A, Azizi F, Valizadeh M, Ziadlou M, **Hosseinpahan F**. *Incidence of obesity and its predictors in children and adolescents in 10 years of follow up: Tehran lipid and glucose study (TLGS)*. BMC Pediatr. 2018 Jul 25;18(1):245.
60. Vakilshahrbabaki, HS; Dehghan, P; **Hosseinpahan, F** ; Asghari, F; Soltanzadi, A. *Association between Non-Alcoholic Fatty Liver Disease and Carotid Intima-Media Thickness in Overweight and Obese Children*. Journal of Research in Medical and Dental Science. 2018 MAY. 6 (3): 313-318.
61. Barzin, M; Motamedi, MAK ; Khalaj, A; Serahati, S; Khalili, D; Morakabati, A; Valizadeh, M ; Azizi, F; **Hosseinpahan, F**; Rakhshani, N . *Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Bariatric Patients: Tehran Obesity Treatment Study (TOTS)*. Hepatitis Monthly. 2018 MAY. 18 (5).
62. Azizi F, Mehran L, **Hosseinpahan F**, Delshad H, Amouzegar A. *Secondary and tertiary preventions of thyroid disease*. Endocrine research. 2018; *Pediatric Endocrinology Reviews* . 4(3), pp. 218-224.
63. Esteghamati A, **Hosseinpahan F**, Jahed SA, Harati H, Astaneh MTCB, Kaykhanzadeh H, Sedaghat S. *GABRIC Diabetes School: an innovative education centre for people with diabetes*. East Mediterr Health J. 2018 Apr 5;24(1):99-103.
64. Kazemijalish H, Ramezani Tehrani F, Behboudi-Gandevani S, Khalili D, **Hosseinpahan F**, Azizi F. *A Population-Based Study of the Prevalence of Abnormal Uterine Bleeding and its Related Factors among Iranian Reproductive-Age Women: An Updated Data*. Archives of Iranian medicine. 2017;20(9):558-63.
65. Kazemi Jalish H, Ramezani Tehrani F, Behboudi-Gandevani S, **Hosseinpahan F**, Khalili D, Cheraghi L, et al. *Polycystic ovary syndrome is a risk factor for diabetes and prediabetes in middle-aged but not elderly women: a long-term population-based follow-up study*. Fertility and sterility. 2017;108(6):1078-84.
66. Stykarsdottir U, Helgason H, Sigurdsson A, Norddahl GL, Agustsdottir AB, Reynard LN, et al. *Corrigendum: Whole-genome sequencing identifies rare genotypes in COMP and CHADL associated with high risk of hip osteoarthritis*. Nat Genet. 2017;49(8):ng0817-1286b.
67. Abdi H, **Hosseinpahan F**, Azizi F, Hadaegh F, Amouzegar A. *Screening for Dysglycemia: A Comment on Classification and Diagnosis of Diabetes in American Diabetes Association Standards of Medical Care in Diabetes-2016*. Arch Iran Med. 2017;20(6).
68. Rostami M, Ramezani Tehrani F, Simbar M, **Hosseinpahan F**, Alavi Majd H. *Rationale and Design of Khuzestan Vitamin D Deficiency Screening Program in Pregnancy: A*

- Stratified Randomized Vitamin D Supplementation Controlled Trial*. JMIR Res Protoc. 2017;6(4).
69. Styrkarsdottir U, Helgason H, Sigurdsson A, Norddahl GL, Agustsdottir AB, Reynard LN, **et al**. Whole-genome sequencing identifies rare genotypes in COMP and CHADL associated with high risk of hip osteoarthritis. *Nat Genet*. 2017;49(5):801-5.
  70. Eftekhazadeh A, Asghari G, Serahati S, **Hosseinpahan F**, Azizi A, Barzin M, et al. Predictors of incident obesity phenotype in nonobese healthy adults. *Eur J Clin Invest*. 2017;47(5):357-65.
  71. Azizi F, Mehran L, **Hosseinpahan F**, Delshad H, Amouzegar A. *Primordial and Primary Preventions of Thyroid Disease*. *Int J Endocrinol Metab*. 2017 Oct 7;15(4).
  72. Mirzaei B, Abdi H, Serahati S, Barzin M, Niroomand M, Azizi F, **et al**. *Cardiovascular risk in different obesity phenotypes over a decade follow-up: Tehran Lipid and Glucose Study*. *Atherosclerosis*. 2017;258:65-71.
  73. Barzin M, Motamedi MA, Serahati S, Khalaj A, Arian P, Valizadeh M, **et al**. Comparison of the Effect of Gastric Bypass and Sleeve Gastrectomy on Metabolic Syndrome and its Components in a Cohort: Tehran Obesity Treatment Study (TOTS). *Obes Surg*. 2017;4(10):016-2526
  74. Asghari G, Eftekhazadeh A, **Hosseinpahan F**, Ghareh S, Mirmiran P, Azizi F. Instability of different adolescent metabolic syndrome definitions tracked into early adulthood metabolic syndrome: Tehran Lipid and Glucose Study (TLGS). *Pediatr Diabetes*. 2017;18(1):59-66.
  75. Doustmohamadian S, Serahati S, Barzin M, Keihani S, Azizi F, **Hosseinpahan F**. Risk of all-cause mortality in abdominal obesity phenotypes: Tehran Lipid and Glucose Study. *NutrMetab Cardiovasc Dis*. 2017 Mar;27(3):241-248. doi: 10.1016/j.numecd.2016.11.123. Epub 2016 Dec 5
  
  76. Barzin M, Khalaj A, Motamedi MA, Shapoori P, Azizi F, **Hosseinpahan F**. *Safety and effectiveness of sleeve gastrectomy versus gastric bypass: one-year results of Tehran Obesity Treatment Study (TOTS)*. *Gastroenterol Hepatol Bed Bench*. 2016;9(Suppl1):S62-S9.
  77. Motamed B, Eftekhazadeh A, **Hosseinpahan F**, Tohidi M, Hasheminia M, Azizi F. The relation between changes in thyroid function and anthropometric indices during long-term follow-up of euthyroid subjects: the Tehran Thyroid Study (TTS). *Eur J Endocrinol*. 2016;175(4):247-53.
  78. Hosseinzadeh-Attar MJ, Golpaie A, Foroughi M, **Hosseinpahan F**, Zahediasl S, Azizi F. The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome. *J Endocrinol Invest*. 2016;39(8):917-22.
  79. **Hosseinpahan F**, Mirbolouk M, Mossadeghkhah A, Barzin M, Serahati S, Delshad H, et al. *Incidence and potential risk factors of obesity among Tehranian adults*. *Prev Med*. 2016;82(**IF:2.893**):99-104.
  80. **Hosseinpahan F**, Barzin M, Mirbolouk M, Abtahi H, Cheraghi L, Azizi F. *Lipid accumulation product and incident cardiovascular events in a normal weight population: Tehran Lipid and Glucose Study*. *European Journal of Preventive Cardiology*. 2016;23(2):187-93.



81. Ghazi AA, **Hosseinpanah F**, Abdi H, Hedayati M, Hasheminia M, Ghazi S, et al. *Effect of Different Doses of Oral Cholecalciferol on Serum 1,25(OH)<sub>2</sub>D in Vitamin D Deficient Schoolchildren*. Horm Metab Res. 2016;48(6):394-8.
82. Ejtahed HS, Shab-Bidar S, **Hosseinpanah F**, Mirmiran P, Azizi F. *Estimation of Vitamin D Intake Based on a Scenario for Fortification of Dairy Products with Vitamin D in a Tehranian Population, Iran*. J Am Coll Nutr. 2016;35(5):383-91.
83. Barzin M, **Hosseinpanah F**, Motamedi MA, Shapoori P, Arian P, Daneshpour MA, et al. *Bariatric Surgery for Morbid Obesity: Tehran Obesity Treatment Study (TOTS) Rationale and Study Design*. Jmir Research Protocols. 2016;5(1):**IF: 4.5**
84. Asgari S, Barzin M, **Hosseinpanah F**, Hadaegh F, Azizi F, Khalili D. *Obesity Paradox and Recurrent Coronary Heart Disease in a Population-Based Study: Tehran Lipid and Glucose Study*. Int J Endocrinol Metab. 2016;14(2):**IF: ندارد**.
85. Moslehi, N., Hosseini-Esfahani, F., **Hosseinpanah, F.**, Mirmiran, P., Azizi, F. *Patterns of food consumption and risk of type 2 diabetes in an Iranian population: A nested case-control study*. Nutrition and Dietetics. 2016. 169-176 pp.
86. Tehrani FR, Montazeri SA, **Hosseinpanah F**, Cheraghi L, Erfani H, Tohidi M, et al. *Trend of cardio-metabolic risk factors in polycystic ovary syndrome: A population-based prospective cohort study*. Plos One. 2015;10(9):**IF: 3.05**).
87. Moslehi N, Shab-Bidar S, Mirmiran P, **Hosseinpanah F**, Azizi F. *Determinants of parathyroid hormone response to vitamin D supplementation: a systematic review and meta-analysis of randomised controlled trials*. Br J Nutr. 2015;114(9):1360-74.
88. Maleki I, Taghvaei T, Barzin M, Amin K, Khalilian A. *Validation of the Persian version of the inflammatory bowel disease questionnaire (IBDQ) in ulcerative colitis patients*. Caspian J Intern Med. 2015;6(1):20-4.
89. Keihani S, **Hosseinpanah F**, Barzin M, Serahati S, Doustmohamadian S, Azizi F. *Abdominal obesity phenotypes and risk of cardiovascular disease in a decade of follow-up: The Tehran Lipid and Glucose Study*. Atherosclerosis. 2015;238(2):256-63.
90. Kazemijaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, Khalili D, **Hosseinpanah F**, Azizi F. *The prevalence of menstrual disorders in reproductive aged women and its related factors*. Iranian Journal of Endocrinology and Metabolism. 2015;17(2):105-12. Epub .
91. Kazemijaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, **Hosseinpanah F**, Khalili D, Azizi F. *The Prevalence and Causes of Primary Infertility in Iran: A Population-Based Study*. Global journal of health science. 2015;7(6):226-32.
92. **Hosseinpanah F**, Salehpour M, Asghari G, Barzin M, Mirmiran P, Hatami H, et al. *"Adolescent metabolic phenotypes and early adult metabolic syndrome: Tehran lipid and glucose study"*. Diabetes Research and Clinical Practice. 2015;109(2):287-92.
93. Heidari Z, **Hosseinpanah F**, Barzin M, Safarkhani M, Azizi F. *Mother-daughter correlation of central obesity and other noncommunicable disease risk factors: Tehran lipid and glucose study*. Asia-Pacific Journal of Public Health. 2015;27(2):NP341-NP9.
94. Eshtiaghi R, Keihani S, **Hosseinpanah F**, Barzin M, Azizi F. *Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: The Tehran Lipid and Glucose Study*. International Journal of Obesity. 2015;39(3):514-9.

95. Barzin M, Keihani S, **Hosseinpanah F**, Serahati S, Ghareh S, Azizi F. *Rising trends of obesity and abdominal obesity in 10 years of follow-up among Tehranian adults: Tehran Lipid and Glucose Study (TLGS)*. Public Health Nutr. 2015;18(16):2981-9.
96. Amiri P, Ghofranipour F, Jalali-Farahani S, Ahmadi F, **Hosseinpanah F**, Hooman HA, et al. *Inventory of determinants of obesity-related behaviors in adolescents: Development and psychometric characteristics*. International Journal of Endocrinology and Metabolism. 2015;13(3).
97. Zarkesh M, **Hosseinpanah F**, Barzin M, Hosseinzadeh N, Guity K, Daneshpour MS, et al. *Recurrence Risk Ratio of Siblings and Familial Aggregation of the Metabolic Syndrome among Tehranian Population*. Archives of Iranian Medicine. 2014;17(6):411-6.
98. Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, et al. *Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease*. World Journal of Gastroenterology. 2014;20(35):12566-73.
99. **Hosseinpanah F**, Nazeri P, Ghareh S, Tohidi M, Azizi F. *Predictors of the incident metabolic syndrome in healthy obese subjects: a decade of follow-up from the Tehran Lipid and Glucose Study*. European Journal of Clinical Nutrition. 2014;68(3):295-9.
100. **Hosseinpanah F**, Barzin M, Keihani S, Tehrani FR, Azizi F. *Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study*. Clinical Endocrinology. 2014;81(1):93-9.
101. **Hosseinpanah F**, Barzin M, Erfani H, Serahati S, Tehrani FR, Azizi F. *Lipid accumulation product and insulin resistance in Iranian PCOS prevalence study*. Clinical Endocrinology. 2014;81(1):52-7.
102. **Hosseinpanah F**, Asghari G, Barzin M, Ghareh S, Azizi F. *Pediatric obesity and adult metabolic syndrome Reply*. Journal of Pediatrics. 2014;164(6):1502-3.
103. Barzin M, **Hosseinpanah F**, Serahati S, Salehpour M, Nassiri AA, Azizi F. *Changes in waist circumference and incidence of chronic kidney disease*. European Journal of Clinical Investigation. 2014;44(5):470-6.
104. Bahadoran Z, Mirmiran P, Yeganeh MZ, **Hosseinpanah F**, Zojaji H, Azizi F. *Complementary and alternative medicinal effects of broccoli sprouts powder on Helicobacter pylori eradication rate in type 2 diabetic patients: A randomized clinical trial*. Journal of Functional Foods. 2014;7:390-7.
105. Amiri P, **Hosseinpanah F**, Jalali-Farahani S, Mehrabi Y, Montazeri A, Azizi F. *Is persistence of metabolic syndrome associated with poor health-related quality of life in non-diabetic Iranian adults? Tehran Lipid and Glucose Study*. Journal of Diabetes Investigation. 2014;5(6):687-93.
106. Amiri P, Deihim T, **Hosseinpanah F**, Barzin M, Hasheminia M, Montazeri A, et al. *Diagnostic values of different definitions of metabolic syndrome to detect poor health status in Iranian adults without diabetes*. Diabetic Medicine. 2014;31(7):854-61.
107. Jalali-Farahani, S., Amiri, P., Ghofranipour, F., **Hosseinpanah, F.**, Hooman, H.A. *Inefficient education and process of obesity in tehranian adolescents: A qualitative study*. Iranian Journal of Endocrinology and Metabolism. 2014. Volume 16, Issue 4, 2014, Pages 262-269.
108. Hosseinpour-Niazi S, Mirmiran P, **Hosseinpanah F**, Fallah-Ghohroudy A, Azizi F. *Association of marital status and marital transition with metabolic syndrome: tehran lipid and glucose study*. Int J Endocrinol Metab. 2014;12(4).

109. **Hosseinpanah F**, Asghari G, Barzin M, Ghareh S, Azizi F. Reply: To PMID 24011762: J Pediatr. 2014 Jun;164(6):1502-3. doi: 10.1016/j.jpeds.2014.02.052. Epub 2014 Mar 31.
110. Shabestari AA, Bahrami-Motlagh H, **Hosseinpanah F**, Heidari K. *Abdominal Fat Sonographic Measurement Compared to Anthropometric Indices for Predicting the Presence of Coronary Artery Disease*. Journal of Ultrasound in Medicine. 2013;32(11):1957-65.
111. Salehpour A, Shidfar F, **Hosseinpanah F**, Vafa M, Razaghi M, Amiri F. *Does vitamin D3 supplementation improve glucose homeostasis in overweight or obese women? A double-blind, randomized, placebo-controlled clinical trial*. Diabetic Medicine. 2013;30(12):1477-81.
112. Noori N, Tabibi H, **Hosseinpanah F**, Hedayati M, Nafar M. *Effects of Combined Lipoic Acid and Pyridoxine on Albuminuria, Advanced Glycation End-Products, and Blood Pressure in Diabetic Nephropathy*. International Journal for Vitamin and Nutrition Research. 2013;83(2):77-85.
113. Malboosbaf R, **Hosseinpanah F**, Mojarrad M, Jambarsang S, Azizi F. *Relationship between goiter and gender: a systematic review and meta-analysis*. Endocrine. 2013;43(3):539-47.
114. **Hosseinpanah F**, Asghari G, Barzin M, Golkashani HA, Azizi F. *Prognostic impact of different definitions of metabolic syndrome in predicting cardiovascular events in a cohort of non-diabetic Tehranian adults*. International Journal of Cardiology. 2013;168(1):369-74.
115. Faam B, **Hosseinpanah F**, Amouzegar A, Ghanbarian A, Asghari G, Azizi F. *Leisure-Time Physical Activity and Its Association With Metabolic Risk Factors in Iranian Adults: Tehran Lipid and Glucose Study, 2005-2008*. Preventing Chronic Disease. 2013;10.
116. Barzin M, **Hosseinpanah F**, Malboosbaf R, Hajsheikholeslami F, Azizi F. *Isolated post-challenge hyperglycaemia and risk of cardiovascular events: Tehran Lipid and Glucose Study*. Diabetes & Vascular Disease Research. 2013;10(4):324-9.
117. Barzin M, Asghari G, **Hosseinpanah F**, Mirmiran P, Azizi F. *The association of anthropometric indices in adolescence with the occurrence of the metabolic syndrome in early adulthood: Tehran Lipid and Glucose Study (TLGS)*. Pediatric Obesity. 2013;8(3):170-7.
118. Amirbaigloo A, **Hosseinpanah F**, Sarvghadi F, Tohidi M, Eskandary PS, Azizi F. *Absence of Association Between Vitamin D Deficiency and Incident Metabolic Syndrome: Tehran Lipid and Glucose Study*. Metabolic Syndrome and Related Disorders. 2013;11(4):236-42.
119. Azizi F, Mirmiran P, Momenan AA, Hadaegh F, Habibi Moeini A, Hosseini F, Zahediasl S, Ghanbarian A, **Hosseinpanah F**. *The effect of community-based education for lifestyle intervention on the prevalence of metabolic syndrome and its components: tehran lipid and glucose study*. Int J Endocrinol Metab. 2013 Summer;11(3):145-53.
120. **Hosseinpanah F**, Asghari G, Barzin M, Ghareh S, Azizi F. *Adolescence metabolic syndrome or adiposity and early adult metabolic syndrome*. J Pediatr. 2013;163(6):1663-9.
121. **Hosseinpanah F**. *Which one is more important, obesity or cardio metabolic risk factors?* Int J Endocrinol Metab. 2013;11(1):1-2.

122. Fam B, Amouzegar A, Arzhan S, Ghanbariyan A, Delshad M, **Hosseinpanah F**, et al. *Association between Physical Activity and Metabolic Risk Factors in Adolescents: Tehran Lipid and Glucose Study*. Int J Prev Med. 2013;4(9):1011-7.
123. Tohidi M, Hasheminia M, Mohebi R, Khalili D, **Hosseinpanah F**, Yazdani B, et al. *Incidence of chronic kidney disease and its risk factors, results of over 10 year follow up in an Iranian cohort*. Plos One. 2012;7(9):27.
124. Salehpour A, Shidfar F, **Hosseinpanah F**, Vafa M, Razaghi M, Hoshiarrad A, et al. *Vitamin D3 and the risk of CVD in overweight and obese women: a randomised controlled trial*. Br J Nutr. 2012;108(10):1866-73.
125. Salehpour A, **Hosseinpanah F**, Shidfar F, Vafa M, Razaghi M, Dehghani S, et al. *A 12-week double-blind randomized clinical trial of vitamin D(3) supplementation on body fat mass in healthy overweight and obese women*. Nutr J. 2012;11(78):1475-2891
126. **Hosseinpanah F**, Borzooei S, Barzin M, Farshadi M, Sarvghadi F, Azizi F. *Diagnostic values of metabolic syndrome definitions for detection of insulin resistance: Tehran Lipid and Glucose Study (TLGS)*. Arch Iran Med. 2012;15(10):606-10.
127. Bahadoran Z, Mirmiran P, **Hosseinpanah F**, Rajab A, Asghari G, Azizi F. *Broccoli sprouts powder could improve serum triglyceride and oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial*. Diabetes Res Clin Pract. 2012;96(3):348-54.
128. Asghari G, **Hosseinpanah F**, Nazeri P, Mirmiran P, Hajsheikholeslami F, Azizi F. *Adult height and risk of coronary heart disease: Tehran Lipid and Glucose Study*. J Epidemiol. 2012;22(4):348-52.
129. Mirmiran, P., Bahadoran, Z., **Hosseinpanah, F.**, Keyzad, A., Azizi, F. *Effects of broccoli sprout with high sulforaphane concentration on inflammatory markers in type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial*. Journal of Functional Foods. 2012. 4(4), pp. 837-841.
130. Zarkesh M, Daneshpour MS, Faam B, Fallah MS, Hosseinzadeh N, Guity K, **Hosseinpanah F**, Momenan AA, Azizi F. *Heritability of the metabolic syndrome and its components in the Tehran Lipid and Glucose Study (TLGS)*. Genet Res (Camb). 2012 Dec;94(6):331-7.
131. **Hosseinpanah F**, Barzin M, Golkashani HA, Nassiri AA, Sheikholeslami F, Azizi F. *Association between moderate renal insufficiency and cardiovascular events in a general population: Tehran lipid and glucose study*. BMC Nephrol. 2012 Jul 16;13:59.
132. Barzin M, **Hosseinpanah F**, Saber H, Sarbakhsh P, Nakhoda K, Azizi F. *Gender Differences Time Trends for Metabolic Syndrome and Its Components among Tehranian Children and Adolescents*. Cholesterol. 2012;2012:804643.
133. Zadeh-Vakili A, Tehrani FR, **Hosseinpanah F**. *Waist circumference and insulin resistance: a community based cross sectional study on reproductive aged Iranian women*. Diabetol Metab Syndr. 2011;3(18):1758-5996.
134. Tehrani FR, Simbar M, Tohidi M, **Hosseinpanah F**, Azizi F. *The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study*. Reprod Biol Endocrinol. 2011;9(39):1477-7827.
135. **Hosseinpanah F**, Yarjanli M, Sheikholeslami F, Heibatollahi M, Eskandary PS, Azizi F. *Associations between vitamin D and cardiovascular outcomes; Tehran Lipid and Glucose Study*. Atherosclerosis. 2011;218(1):238-42.

136. **Hosseinpanah F**, Barzin M, Tehrani FR, Azizi F. *The lack of association between polycystic ovary syndrome and metabolic syndrome: Iranian PCOS prevalence study*. Clin Endocrinol. 2011;75(5):692-7.
137. **Hosseinpanah F**, Barzin M, Sheikholeslami F, Azizi F. *Effect of different obesity phenotypes on cardiovascular events in Tehran Lipid and Glucose Study (TLGS)*. Am J Cardiol. 2011;107(3):412-6.
138. **Hosseinpanah F**, Barzin M, Amiri P, Azizi F. *The trends of metabolic syndrome in normal-weight Tehranian adults*. Ann Nutr Metab. 2011;58(2):126-32.
139. Hosseini-Esfahani F, Bahadoran Z, Mirmiran P, Hosseinpour-Niazi S, **Hosseinpanah F**, Azizi F. *Dietary fructose and risk of metabolic syndrome in adults: Tehran Lipid and Glucose study*. Nutr Metab. 2011;8(1):1743-7075.
140. Barzin M, **Hosseinpanah F**, Fekri S, Azizi F. *Predictive value of body mass index and waist circumference for metabolic syndrome in 6-12-year-olds*. Acta Paediatr. 2011;100(5):722-7.
141. Bahadoran Z, Mirmiran P, **Hosseinpanah F**, Hedayati M, Hosseinpour-Niazi S, Azizi F. *Broccoli sprouts reduce oxidative stress in type 2 diabetes: a randomized double-blind clinical trial*. Eur J Clin Nutr. 2011;65(8):972-7.
142. Amiri P, Ghofranipour F, Ahmadi F, **Hosseinpanah F**, Montazeri A, Jalali-Farahani S, et al. *Barriers to a healthy lifestyle among obese adolescents: a qualitative study from Iran*. Int J Public Health. 2011;56(2):181-9.
143. Bahadoran, Z., Hosseini-Esfahani, F., Mirmiran, P., Mehran, M., **Hosseinpanah, F.**, Azizi, F. *Dietary fructose and cardiovascular disease risk factors in adults: Tehran lipid and glucose study*. Iranian Journal of Endocrinology and Metabolism. 2011. 12(6), pp. 641-646+666.
144. Bahadoran, Z., Mirmiran, P., Mohtadinia, J., (...), **Hosseinpanah, F.**, Azizi, F. *Effects of broccoli sprout powder on fasting serum glucose and lipid profiles in type 2 diabetic patients*. Iranian Journal of Endocrinology and Metabolism. 2011. 13(1), pp. 114
145. **Hosseinpanah, F.**, Sorouri, M., Rambod, M., Azizi, F. *Total duration of breastfeeding is associated with low bone mineral density in Iranian postmenopausal women*. International Journal of Endocrinology and Metabolism. 2011. 8(3), pp. 153-158.
146. Malboosbaf, R., **Hosseinpanah, F.**, Azizi, F., Mojarrad, M., Jambarsang, S. *Difference in goiter prevalence between genders: A metaanalysis of literature*. Iranian Journal of Endocrinology and Metabolism. 2011. 12(6), pp. 641-646+666.
147. Yarjanli, M., **Hosseinpanah, F.**, Sheikholeslami, F., Azizi, F. *Association between vitamin D deficiency and cardiovascular disease*. Iranian Journal of Endocrinology and Metabolism. 2011. 12(5), pp. 520-528+562
148. **Hosseinpanah F**, Pour SH, Heibatollahi M, Moghbel N, Asefzade S, Azizi F. *The effects of air pollution on vitamin D status in healthy women: a cross sectional study*. BMC Public Health. 2010;10(519):1471-2458.
149. **Hosseinpanah F**, Barzin M, Mirmiran P, Azizi F. *Effect of changes in waist circumference on metabolic syndrome over a 6.6-year follow-up in Tehran*. Eur J Clin Nutr. 2010;64(8):879-86.

150. Heidari Z, **Hosseinpanah F**, Shirazian N. *Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor*. *Endocr Pract*. 2010;16(4):669-72.
151. Heidari Z, **Hosseinpanah F**, Mehrabi Y, Safarkhani M, Azizi F. *Predictive power of the components of metabolic syndrome in its development: a 6.5-year follow-up in the Tehran Lipid and Glucose Study (TLGS)*. *Eur J Clin Nutr*. 2010;64(10):1207-14.
152. Ghazi AA, **Hosseinpanah F**, E MA, Ghazi S, Hedayati M, Azizi F. *Effects of different doses of oral cholecalciferol on serum 25(OH)D, PTH, calcium and bone markers during fall and winter in schoolchildren*. *Eur J Clin Nutr*. 2010;64(12):1415-22.
153. Azizi F, Khalili D, Aghajani H, Esteghamati A, **Hosseinpanah F**, Delavari A, et al. *Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity*. *Arch Iran Med*. 2010;13(3):243-4.
154. Azizi F, Hadaegh F, Khalili D, Esteghamati A, **Hosseinpanah F**, Delavari A, et al. *Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity*. *Arch Iran Med*. 2010;13(5):426-8.
155. Amiri P, **Hosseinpanah F**, Rambod M, Montazeri A, Azizi F. *Metabolic syndrome predicts poor health-related quality of life in women but not in men: Tehran Lipid and Glucose Study*. *J Womens Health*. 2010;19(6):1201-7.
156. Amiri P, E MA, Jalali-Farahani S, **Hosseinpanah F**, Varni JW, Ghofranipour F, et al. *Reliability and validity of the Iranian version of the Pediatric Quality of Life Inventory 4.0 Generic Core Scales in adolescents*. *Qual Life Res*. 2010;19(10):1501-8.
157. Afkhami-Ardekani M, Zahedi-Asl S, Rashidi M, Atifah M, **Hosseinpanah F**, Azizi F. *Incidence and trend of a metabolic syndrome phenotype among Tehranian adolescents: findings from the Tehran Lipid and Glucose Study, 1998-2001 to 2003-2006*. *Diabetes Care*. 2010;33(9):2110-2.
  
158. Amiri, P., Ghofranipour, F., Jalali-Farahani, S., (...), **Hosseinpanah, F.**, Hooman, H. *Mothers' perceptions on familial correlates of overweight and obesity related behaviors in adolescents: A qualitative study*. *Iranian Journal of Endocrinology and Metabolism*. 2010.12(2), pp. 145-152+198
159. Tavakkoli, D.A., **Hosseinpanah, F.**, Tahbaz, F., (...), Tavakkoli, D.R., Hedayati, M. *Effects of conjugated linoleic acid supplementation on body composition and leptin concentration in post-menopausal women*. *Iranian Journal of Endocrinology and Metabolism*.2010. 12(1), pp. 48-59+84
160. Noori, N., Tabibi, H., **Hosseinpanah, F.**, Hedayati, M., Nafar, M. *Effects of combined administration of lipoic acid and pyridoxine on serum systemic and vascular inflammatory factors in patients with diabetic nephropathy*. *Iranian Journal of Endocrinology and Metabolism*.2010. 12(2), pp. 99-110+194
161. Amiri, P., Ghofranipour, F., Ahmadi, F., Hooman, H., **Hosseinpanah, F.**, Jalali-Farahani, S. *Personal barriers to life style modification in overweight/obese adolescents: A qualitative study*. *Iranian Journal of Endocrinology and Metabolism*.2010. 11(5), pp. 521-529+601
162. Heidari, Z., **Hosseinpanah, F.**, Azizi, F. *Familial clustering of central obesity and cardiovascular disease risk factors*. *Iranian Journal of Endocrinology and Metabolism*.2010. 12(4).

163. Chiti, H., **Hosseinpahan, F.**, Mehrabi, Y., Azizi, F. *The prevalence of metabolic syndrome in adolescents with varying degrees of body weight: Tehran Lipid and Glucose Study (TLGS)*. Iranian Journal of Endocrinology and Metabolism.2010. 11(6), pp. 625-637+730.
164. Heidari, Z., **Hosseinpahan, F.**, Mehrabi, Y., Azizi, F. *Evaluation of power of components of metabolic syndrome for prediction of its development: A 6.5 year longitudinal study in Tehran Lipid and Glucose Study (TLGS)*. Iranian Journal of Endocrinology and Metabolism.2010. 11(5), pp. 530-542+602.
165. Mohammadzadeh, G.H., Zarghami, N., Zahedi Asl, S., **Hosseinpahan, F.** *Relationship between DHEA and DHEA-S with anthropometric indices in women with different grades of obesity*. Iranian Journal of Endocrinology and Metabolism.2010. 11(5), pp. 510-520+600.
166. Rambod M, **Hosseinpahan F**, Ardakani EM, Padyab M, Azizi F. *Fine-tuning of prediction of isolated impaired glucose tolerance: a quantitative clinical prediction model*. Diabetes Res Clin Pract. 2009;83(1):61-8
167. Noori N, **Hosseinpahan F**, Nasiri AA, Azizi F. *Comparison of overall obesity and abdominal adiposity in predicting chronic kidney disease incidence among adults*. J Ren Nutr. 2009;19(3):228-37.
168. Nafar M, Noori N, Jalali-Farahani S, **Hosseinpahan F**, Poorrezaghali F, Ahmadpoor P, et al. *Mediterranean diets are associated with a lower incidence of metabolic syndrome one year following renal transplantation*. Kidney Int. 2009;76(11):1199-206.
169. **Hosseinpahan F**, Kasraei F, Nassiri AA, Azizi F. *High prevalence of chronic kidney disease in Iran: a large population-based study*. BMC Public Health. 2009;9(44):1471-2458.
170. **Hosseinpahan F**, Barzin M, Eskandary PS, Mirmiran P, Azizi F. *Trends of obesity and abdominal obesity in Tehranian adults: a cohort study*. BMC Public Health. 2009;9(426):1471-2458.
171. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. *Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II*. Trials. 2009;10(5):1745-6215.
172. **Hosseinpahan, F.**, Rambod, M., Ardakani, A.M., Azizi, F. *Identifying isolated impaired glucose tolerance using common clinical data Tehran lipid & glucose study*. Iranian Journal of Endocrinology and Metabolism.2009. 10(5).
173. Borzouei, Sh., **Hosseinpahan, F.**, Azizi, F. *Agreement level of definitions of the metabolic syndrome by modified ATP III and IDF with insulin resistance in The Lipid and Glucose Study (TLGS)*. Iranian Journal of Endocrinology and Metabolism.2009. 10(5).
174. **Hosseinpahan F**, Rambod M, Hossein-nejad A, Larijani B, Azizi F. *Association between vitamin D and bone mineral density in Iranian postmenopausal women*. J Bone Miner Metab. 2008;26(1):86-92.
175. **Hosseinpahan F**, Rambod M, Azizi F. *Likelihood of having isolated postchallenge hyperglycemia in an Iranian urban population*. Diabetes Res Clin Pract. 2008;79(3):490-6.
176. Esmaeili-Mahani S, Fathi Y, Motamedi F, **Hosseinpahan F**, Ahmadiani A. *L-type calcium channel blockade attenuates morphine withdrawal: in vivo interaction between L-type calcium channels and corticosterone*. Horm Behav. 2008;53(2):351-7.

177. Ahmadi-Abhari S, Soltani A, **Hosseinpanah F**. *Knowledge and attitudes of trainee physicians regarding evidence-based medicine: a questionnaire survey in Tehran, Iran*. J Eval Clin Pract. 2008;14(5):775-9.
178. **Hosseinpanah F**, Rambod M, Azizi F. Population attributable risk for diabetes associated with excess weight in Tehranian adults: a population-based cohort study. BMC Public Health. 2007;7:328.
179. Jahed, A., **Hosseinpanah, F.**, Azizi, F. *Prevalence and predictive factors of LADA "latent autoimmune diabetes in adults" in newly diagnosed diabetics of Tehran lipid and glucose study*. Iranian Journal of Diabetes and Lipid Disorders.2007. 7(1), pp. E5 .
180. **Hosseinpanah, F.**, Rambod, M., Azizi, F. *Prevalence and predictors of isolated postchallenge hyperglycemia in Tehran's urban population: Tehran Lipid and Glucose Study (TLGS)*. Iranian Journal of Diabetes and Lipid Disorders.2007. 6(3), pp. 39-49+E30.
181. **Hosseinpanah, F.**, Rambod, M., Reza Ghaffari, H.R., Azizi, F. *Predicting isolated postchallenge hyperglycaemia: A new approach; Tehran Lipid and Glucose Study (TLGS)*. Diabetic Medicine.2006. 23(9), pp. 982-989.

### **Qualifications of Skills:**

- Evidence based medicine
- Research methodology
- Biostatistics
- Medical Scientific Writing

**H-index:** Scopus, 32\

**Citations:** \ ۱۳۵۶۱۱\ 3687

**Farhad Hosseinpanah, M.D.**

Obesity Research Center  
Research Institute for Endocrine Sciences  
Shahid Beheshti University of Medical Sciences, Tehran, Iran  
P.O.Box: 19395-4763  
Phone: +98-21-22409309  
Cell: +98-912-343 1927  
Fax: +98-21-22402463  
Email: [fhospanah@endocrine.ac.ir](mailto:fhospanah@endocrine.ac.ir)